http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
5-fluorouracil이 근간이 된 화학요법에 실패한 진행성 위암에서 Docetaxel과 Cisplatin 복합화학요법
이효락,박세훈,송서영,박준오,이순일,김기현,김원석,정철원,임영혁,이홍기,박근칠,박찬형,강원기 대한내과학회 2002 대한내과학회지 Vol.62 No.1
Background : There is no effective treatment in patients with advanced gastric cancer failed to first-line chemotherapy. Taxane is one of new drugs identified as having substantial activity in gastric cancer. We performed a phase II trial to evaluate the efficacy and toxicity of docetaxel plus cisplatin regimen as a salvage chemotherapy for advanced gastric cancer failed to 5-fluorouracil (5-FU)-based chemotherapy. Methods : Metastatic or recurrent gastric cancer patients failed to 5-FU-based regimen with an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2 were eligible in this trial. Docetaxel (60 mg/m2) was infused over 1 hour, before cisplatin (60 mg/m2) infused over 2 hours on day 1, once every 3 weeks until disease progression or unacceptable toxicity was detected. Response to treatment was assessed every two or three cycles. Results : From October 1999 to December 2000, forty-one patients were enrolled in this study. Twenty-eight of forty-one patients were assessable for response. Partial response was observed in seven patients and stable disease in four patients. The response rate was 25.0% (95% confidence interval: 20.4~29.6%) and median duration of response was 22 weeks (range: 11~53 weeks). The median survival of all enrolled patients was 24 weeks (range: 7~65 weeks). For a total of 112 cycles of chemotherapy, grade 3 and 4 toxicity was 8.9% for neutropenia, 4.5% for nausea/vomiting and 1.8% for mucositis. Conclusion : Salvage chemotherapy with docetaxel plus cisplatin regimen in gastric cancer was active with acceptable toxicities.(Korean J Med 62:83-89, 2002) 목적 : 진행성 위암 환자에서 일차화학요법에 실패할 경우에 사용할 수 있는 효과적인 치료는 현재까지 없는 실정이다. Taxane은 위암에 효과가 있다고 알려진 신약 중의 하나로, 저자들은 5-FU가 근간이 된 일차화학요법에 실패한 진행성 위암 환자를 대상으로 docetaxel과 cisplatin 복합화학요법을 이용한 구제화학요법의 치료효과 및 부작용을 평가하고자 제 2상 임상연구를 시행하였다.
5-fluorouracil 이 근간이 된 화학요법에 실패한 진행성 위암에서 Docetaxel 과 Cisplatin 복합화학요법
이효락(Hyo Rak Lee),박세훈(Se Hoon Park),송서영(Seo Young Song),박준오(Joon Oh Park),이순일(Soon Il Lee),김기현(Ki Hyun Kim),김원석(Won Seog Kim),정철원(Chul Won Jung),임영혁(Young Hyuck Im),이홍기(Hong Ghi Lee),박근칠(Keun Chil Park 대한내과학회 2002 대한내과학회지 Vol.62 No.1
N/A Background: There is no effective treatment in patients with advanced gastric cancer failed to first-line chemotherapy. Taxane is one of new drugs identified as having substantial activity in gastric cancer. We performed a phase II trial to evaluate the efficacy and toxicity of docetaxel plus cisplatin regimen as a salvage chemotherapy for advanced gastric cancer failed to 5-fluorouracil (5-FU)-based chemotherapy. Methods: Metastatic or recurrent gastric cancer patients failed to 5-FU-based regimen with an Eastern Cooperative Oncology Group (ECOG) performance score≤2 were eligible in this trial. Docetaxel (60mg/㎡) was infused over 1 hour , before cisplatin (60 mg/㎡) infused over 2 hours on day 1, once every 3 weeks until disease progression or unacceptable toxicity was detected. Response to treatment was assessed every two or three cycles. Results: From October 1999 to December 2000, forty-one patients were enrolled in this study. Twenty-eight of forty-one patients were assessable for response. Partial response was observed in seven patients and stable disease in four patients. The response rate was 25.0% (95% confidence interval: 20.4-29.6%) and median duration of response was 22 weeks (range: 11-53 weeks). The median survival of all enrolled patients was 24 weeks (range: 7-65 weeks). For a total of 112 cycles of chemotherapy, grade 3 and 4 toxicity was 8.9% for neutropenia, 4.5% for nausea/vomiting and 1.8% for mucositis. Conclusion: Salvage chemotherapy with docetaxel plus cisplatin regimen in gastric cancer was active with acceptable toxicities. (Korean J Med 62:83-89, 2002)
유영진,이효락,김성록 대한암학회 2008 Cancer Research and Treatment Vol.40 No.3
Purpose: Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients. Materials and Methods: The eligibility criteria were as follows: pathologically confirmed NSCLC, an age ≥ 65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m² was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration. Results: From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65∼75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4∼64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy. Conclusions: Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.
강건희,김광실,이효락,유영진,김성록 대한암학회 2008 Cancer Research and Treatment Vol.40 No.3
Purpose: We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. Materials and Methods: Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m² on day 1, 5-FU 1 g/m²/ day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m² on day 1 were administered. This regimen was repeated every 3 weeks. Results: A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0∼77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed. Conclusions: The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.